GENOMIC ANALYSIS OF PRIMARY AND SECONDARY MYELOFIBROSIS
REDEFINES THE PROGNOSTIC IMPACT OF ASXL1 MUTATIONS: A FIM STUDY
Damien Luque Paz1, Jérémie Riou2, Emmanuelle Verger3, Bruno Cassinat3, Aurélie Chauveau4, Jean-
Christophe Ianotto5, Brigitte Dupriez6, Françoise Boyer-Perrard7, Maxime Renard7, Olivier Mansier8,
Anne Murati9, Jérome Rey9, Gabriel Etienne10, Véronique Demas11, Suzanne Tavitian12, Olivier
Nibourel13, Stéphane Girault14, Yannick Le Bris15, Francois Girodon16, Dana Ranta17, Jean-Claude
Chomel18, Pascale Cony-Makhoul19, Pierre Sujobert20, Margot Robles21, Raouf Ben Abdelali22, Olivier
Kosmider23, Laurane Cottin24, Lydia Roy25, Ivan Sloma26, Fabienne Vacheret27, Mathieu Wemeau28,
Pascal Mossuz29, Slama Borhane30, Vincent Cussac31, Guillaume Denis32, Anouk walter-Petrich33,
Barbara Burroni34, Nathalie Jezequel35, Stéphane Giraudier3, Eric Lippert4, Gérard Socié36, Jean-Jacques
Kiladjian37 and Valérie Ugo38
(1)Université d'Angers, Inserm, CRCINA, ANGERS, France
(2)INSERM 1066 MINT, ANGERS, France
(3)Service de Biologie Cellulaire, Hôpital Saint-Louis, Paris, France
(4)CHU Brest, Laboratoire d'Hématologie, BREST, France
(5)Hematolgie Clinique CHU Brest, Brest, France
(6)CH Lens, Lens, France
(7)CHU Angers, Angers, France
(8)CHU Bordeaux, Bordeaux, France
(9)IPC Marseille, Marseille, France
(10)Institut Bergonié, Bordeaux, France
(11)CHU Toulouse, Toulouse, France
(12)Hematology Department, IUCT-Oncopôle, Toulouse, France
(13)CHRU Lille, Lille, France
(14)CHU Limoges, Limoges, France
(15)Hematology Biology, CHU Nantes, Nantes, France
(16)CHU Dijon, Dijon, France
(17)9Centre Hospitalier Universitaire, Nancy, France
(18)CHU Poitiers, Poitiers, France
(19)Service d’Hématologie, Hôpital d’Annecy Genevois, Metz-Tessy, France
(20)Laboratory of molecular biology and cytogenetics, Centre Hospitalier Lyon Sud, Pierre Benite,
France
(21)CH Périgueux, Périgueux, France
(22)CERBA, Paris, France
(23)Institut Cochin - U1016, Paris, France
(24)CHU Angers, Laboratoire d'Hématologie, ANGERS, France
(25)AP-HP, Hopital Henri Mondor, Service d’Hematologie clinique, Creteil, France
(26)AP-HP, Hopital Henri Mondor, Departement d’Hematologie et Immunologie, Creteil, France
(27)CH Perpignan, Perpignan, France
(28)CH Roubaix, Roubaix, France
(29)CHU Grenoble, Grenoble, France
(30)hematology, avignon, France
(31)CH Le Mans, Le Mans, France
(32)CH Rochefort, Rochefort, France
(33)ECSTRRA Team U1153, INSERM, Paris, France
(34)APHP, Paris, France
(35)CHU Brest, Brest, France
(36)APHP St Louis, Paris, France,
(37)Hôpital Saint-Louis & Université de Paris, Paris, France
SCIENTIFIC PROGRAMME
SESSION I
OPTIMIZING
CYTOREDUCTION
SESSION II
MANAGEMENT OF CML
WITH TKI
SESSION III
MPN RISK
STRATIFICATION
INCLUDING VASCULAR
EVENTS
DEBATE 1
INTERFERON ALPHA
SHOULD BE FRONT LINE
THERAPY IN ALL ET/PV
PATIENTS
ROUNDTABLE 1
INFECTIONS IN
MYELOPROLIFERATIVE
DISORDERS, INCLUDING
CML
ROUNDTABLE 2
PREGNANCY AND
PARENTING
DEBATE 2
ALLOGENEIC STEM CELL
TRANSPLANTATION
SHOULD BE CONSIDERED
THIRD LINE OPTION IN
CHRONIC PHASE CML
SESSION IV
EVOLVING THERAPIES
IN MYELOFIBROSIS
SESSION V
MANAGEMENT OF
ADVANCED AND UNUSUAL
DISEASE (MPN AND CML)
SESSION VI
TREATMENT FREE
REMISSION IN CML
KEYNOTE LECTURE
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FO R A POSTER
PRESENTATION
DISCLOSURES